NCT07536087Recruiting
Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Cystic Neoplasms and Pancreatic Neuroendocrine Tumors
Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Cystic Neoplasms and Neuroendocrine Tumors
Source: ClinicalTrials.gov · Last updated 17 Apr 2026
Brief summary (registry, in English)
The primary aim of this study is to evaluate the technical feasibility and effectiveness of endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) in the treatment of pancreatic cystic neoplasms (PCNs) and pancreatic neuroendocrine tumors (pNETs) in patients who are not suitable candidates for surgical treatment or who refuse surgery. EUS-RFA, as a minimally invasive therapeutic option, may potentially reduce the need for intensive imaging surveillance, prevent further progression of these lesions, and serve as a bridging therapy in selected patients for whom surgical intervention may be considered in the future. At the same time, EUS-RFA could contribute to reducing overtreatment, thereby lowering the risk of complications associated with surgical procedures and leading to an overall reduction in healthcare costs. The secondary objectives of the study are to evaluate the safety profile of EUS-RFA, including the incidence and severity of adverse events both in the early postoperative period and during the first year of follow-up, as well as to assess the long-term efficacy of EUS-RFA, including disease progression.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 11 Apr 2026
- Start date
- 11 Apr 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Institute for Clinical and Experimental Medicine
- Diseases
- Neuroendocrine tumours, Pancreatic cancer
- NCT number
- NCT07536087
What you commit to
- Study type: Interventional
- Planned participants: 50
- From 11 Apr 2026 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known bleeding disorder that cannot be sufficiently corrected with medication
Other
- Use of anticoagulants that cannot be discontinued
- Physical and/or psychological inability to understand the aims of the research and to adequately cooperate
- Pregnancy
- Inability to sign the informed consent
Who the study is looking for
- Consensual indication to EUS-guided RFA treatment made in a multidisciplinary team
- Capability of giving informed consent PCN Inoperability or refusal of surgery
- Branch duct IPMN (BD-IPMN) with worrisome features:
- Jaundice
- High grade dysplasia or cancer
- Solid mass/nodule \> 5mm
- Main pancreatic duct dilation \> 10mm Or at least one (patients without comorbidities) or at least two (patient with comorbidities) of the following risk features:
- CA 19-9\> 37 U/ml
- Increase in size \> 5mm/year
- Dilation of the main pancreatic duct between 5-10mm
- Size ≥ 40mm
- Symptoms (new onset of diabetes, acute pancreatitis)
- Nodule \< 5mm Pancreatic NET
- Size \< 2 cm
- Histological proof in non-functional lesions/histological proof or clinical proof in functional lesions
- 68Ga-DOTATATE PET/CT positive for a pancreatic lesion and negative for lymph nodes, liver, and other distant metastases
- G1 or G2 (\<5 %) histology
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institute for Clinical and Experimental Medicine, Department of Gastroenterology and Hepatology Coordinator of this site? Confirm its status | Prague | Czechia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.